Market Place
Sourcing Support
Jaguar Health Launches FDA-Approved Gelclair In The U.S.
16 Oct 2024 //
ACCESSWIRE
Jaguar Health Submits Abstract For Cancer Diarrhea Study
08 Oct 2024 //
ACCESSWIRE
MASCC Webinar on GI Toxicities Made Possible by Grant From Napo
07 Dec 2023 //
ACCESSWIRE
Breast Cancer Related Results of Napo Supported Study on Quality of Life
09 Nov 2023 //
ACCESSWIRE
Napo Accepted to Present Results of Phase 3 for Cancer Therapy-Related Diarrhea
25 Oct 2023 //
ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose
05 Dec 2022 //
ACCESSWIRE
Jaguar Health Completes Third-party, Investigator-Initiated Study of Crofelemer
01 Feb 2022 //
ACCESSWIRE
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline
07 Oct 2021 //
YAHOO
Napo Pharmaceuticals and Napo EU S.p.A. to develop Crofelemer and Lechlemer
19 Aug 2021 //
YAHOO FINANCE
Napo , Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment
27 May 2021 //
BIOSPACE
Napo Signs Agreement with Alamo Services to Launch National Sales Force Mytesi™
08 Feb 2017 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.